Plant-based expression platforms to produce high-value metabolites and proteins

Aditya Kulshreshtha1, Shweta Sharma2†, Carmen S. Padilla1 and Kranthi K. Mandadi1,3,4*

1Texas A&M AgriLife Research and Extension Center, Weslaco, TX, United States, 2Department of Veterinary Pathology, Dr. GCN College of Veterinary & Animal Sciences, CSK Himachal Pradesh Agricultural University, Palampur, India, 3Department of Plant Pathology and Microbiology, Texas A&M University, College Station, TX, United States, 4Institute for Advancing Health Through Agriculture, Texas A&M AgriLife, College Station, TX, United States

Plant-based heterologous expression systems can be leveraged to produce high-value therapeutics, industrially important proteins, metabolites, and bioproducts. The production can be scaled up, free from pathogen contamination, and offer post-translational modifications to synthesize complex proteins. With advancements in molecular techniques, transgenics, CRISPR/Cas9 system, plant cell, tissue, and organ culture, significant progress has been made to increase the expression of recombinant proteins and important metabolites in plants. Methods are also available to stabilize RNA transcripts, optimize protein translation, engineer proteins for their stability, and target proteins to subcellular locations best suited for their accumulation. This mini-review focuses on recent advancements to enhance the production of high-value metabolites and proteins necessary for therapeutic applications using plants as bio-factories.

KEYWORDS
plant secondary metabolites, heterologous production, molecular farming, plant-made secondary metabolites, plant-made therapeutic proteins

1 Introduction

Many plant-based expression systems were developed for the large-scale production of valuable proteins and metabolites used in the pharmaceuticals, nutraceuticals, and cosmetics industries. These platforms are relatively cost-efficient, free from pathogens affecting humans, can synthesize complex proteins with post-translational modifications, and are scalable (Buyel, 2019; Burnett and Burnett, 2020). They can be used to produce vaccines, antibodies, antimicrobial peptides, hormones, growth factors, and industrially essential enzymes. Plants can be also used to produce high-value secondary metabolites.
industries depend on medicinal plants for sourcing SMs (Isah, 2019). Since chemical synthesis is expensive and challenging for many SMs, pharmaceutical industries depend on medicinal plants for sourcing SMs (Isah, 2019). With advancements in molecular techniques and synthetic biology tools, researchers have increased the quantity and quality of plant-made recombinant proteins and SMs. This mini-review summarizes different strategies for the enhanced production of valuable proteins and metabolites using plants as bio-factories for heterologous expression.

2 Heterologous expression of recombinant proteins in plants

Plant molecular farming is the practice of using plant-based platforms to produce high-value recombinant peptides and proteins. These proteins can either be stably or transiently produced, and as per need, they can be directed to accumulate in whole plants, seeds, chloroplasts, fruits, or roots (Xu et al., 2018). Moreover, many plant transformation methods based on Agrobacterium or polyethylene glycol (PEG)-mediated transformation, particle-bombardment, vacuum, and virus-based infiltrations are well established (Joung et al., 2015).

2.1 Approaches to enhance expression of recombinant proteins

2.1.1 Promotor engineering and combinatorial stacking

The promoter is an essential element in regulating transgene expression. As per the need, many different types of promoters, like constitutive, inducible, tissue-specific, and synthetic promoters, are employed. The cauliflower mosaic virus 35S promoter (CaMV 35S), a strong constitutive promoter in either single or multiple copies, is widely used in dicot plants, whereas the maize ubiquitin-1 (Ubi-1) promoter is used to express therapeutic proteins in monocots (Phakham et al., 2021; Mirzaee et al., 2022). Recently, Damaj et al. (2020) reported a combinatorial stacked promoter system to enhance the expression of recombinant bovine lysozyme (BvLz). BvLz is a potent broad-spectrum antimicrobial enzyme used in the food, cosmetic, and agricultural industries. Combinatorial plant transformation and co-expression of BvLz under the control of various constitutive and culm-regulated promoters yielded high levels of expression (up to 11.5% of total soluble protein) in sugarcane culms (Damaj et al., 2020). Similarly, Padilla et al. (2020) successfully enhanced the expression of recombinant Galanthus nivalis L. (snowdrop agglutinin (GNA) in sugarcane and energy cane. GNA possesses antiviral, antifungal, and antitumor activities. Under a single constitutive Ubi-1 promoter, GNA accumulated 0.04% and 0.3% of total soluble protein (TSP) in sugarcane culms and leaves, respectively. Its expression was further increased to 1.8% TSP and 2.3% TSP in sugarcane and energy cane lines, respectively, by co-expressing recombinant GNA under multiple promoters (pUbi-1 and culm-regulated promoters from sugarcane dirigent5-1 and sugarcane bacilliform virus; pUBD5:GNA) from different expression vectors. Moreover, the expression of recombinant GNA in the triple promoter transgenic lines (pUBD5:GNA) was further boosted to 2.7% TSP by inducing promoter activity with salicylic acid (Padilla et al., 2020). These studies demonstrate the great potential of the inducible promoters and combinatorial promoter stacking system to increase the accumulation of high-value therapeutic proteins in plants.

2.1.2 Codon optimization

The native amino-acid codon degeneracy enables the optimization of non-favorable codons within an open reading frame of a protein. Some mRNAs possess cryptic splicing sites, secondary structures, mRNA stability elements, and alternative translation start sites that may negatively affect protein translation and accumulation. The codon optimization process uses synonymous codons without altering the protein amino acid sequence to increase translational efficiency (Webster et al., 2017). For instance, through codon optimization, the expression of stem cell factor (SCF) for ex vivo RBC production increased 25- to 30-fold in tobacco Bright Yellow-2 (BY-2) cells (Wang et al., 2021). In another study, a codon-optimized BvLz was stably expressed in sugarcane culms (Damaj et al., 2020). Further, codon optimization and other approaches enhanced the expression of human interferon-gamma (IFNγ) via bamboo mosaic virus (BaMV) mediated transient expression in Nicotiana benthamiana (Jiang et al., 2019).

2.1.3 Expression using plant virus vectors

Plant viruses infect many crops, ornamentals, and medicinal plant species (Kulshreshtha et al., 2017; Sharma et al., 2019). Many asymptomatic or inactivated viruses have been engineered as chimeric expression vectors to transiently express therapeutic proteins in different plant species. For instance, the tobacco mosaic virus (TMV) was employed to express the receptor binding domain (RBD) of the SARS-CoV-2 spike protein in glycoengineered N. benthamiana. After purification of the protein and vaccination, mice produced RBD-specific antibodies that neutralized the SARS-CoV-2 virus infection in Vero E6 cells (Maharjan et al., 2021). Likewise, the bean yellow
dwarf virus (BeYDV) expressed SARS-CoV-2 RBD and basic fibroblast growth factor (bFGF) in two microalgal species; Chlamydomonas reinhardtii and Chlorella vulgaris (Malla et al., 2021). Similarly, the cowpea mosaic virus (CPMV) and the potato virus X (PVX) expressed vaccine candidates in the N. benthamiana against the hepatitis E virus and the influenza virus, respectively (Mardanova et al., 2017; Zahmanova et al., 2021). These findings underscore the utility of plant viruses to express a wide range of biologics to produce therapeutic molecules rapidly during pandemics.

2.1.4 Suppression of RNA silencing

A potential limitation in any eukaryotic expression system is the inherent host RNA silencing mechanism that may suppress the expression of foreign genes. Fortunately, many plant virus-encoded suppressor proteins can be co-expressed with the gene of interest to suppress host silencing, increasing recombinant protein expression by several folds (Gao et al., 2013). For instance, the co-expression of tombusvirus P19 suppressor led to a 40% increase in the expression of truncated human IFNγ accumulation in N. benthamiana using a BaMV-based vector (Jiang et al., 2019). In another example, PVX and a P19 suppressor were used to express a fusion protein (lhmR) of melittin peptide and gonadotropin-releasing hormone receptor (GnRHR) in N. benthamiana. The purified protein was functional and inhibited the cancerous cells in the MTT assay (Naseri et al., 2020). In a recent study, CRISPR/Cas9 was also employed to knockout N. benthamiana dicer-like proteins 2 and 4 (NbDCL2 and NbDCL4). The knockout plants produced 6.96 folds higher expression of human fibroblast growth factor 1 (FGF1) than wild-type plants (Matsuo, 2022).

2.1.5 Optimization of downstream processing

To enable efficient purification of the recombinant proteins from plant cells, often downstream extraction and processing steps need to be optimized. In the extraction phase, tissue homogenization releases impurities like host cell proteins, enzymes, and phenolic compounds. The phenolic compounds form covalent complexes with recombinant protein in the presence of plant polyphenol oxidases (PPO) and could result in aggregation and precipitation of recombinant protein which ultimately reduces protein yield and quality. Furthermore, many plant proteases can degrade target proteins. These factors can be partially addressed by including broad-spectrum protease inhibitors and antioxidants in the extraction steps (Buyle et al., 2015). In addition, CRISPR/Cas9-based target editing of PPO genes in the host cells can be employed to enhance in planta expression of recombinant therapeutic proteins (Gonzalez et al., 2020). Another alternative is to target proteins via signal sequences to accumulate into specific subcellular compartments such as apoplast, chloroplast, and endoplasmic reticulum (Habibi et al., 2017). Recombinant proteins can subsequently be purified with affinity tags such as maltose-binding protein, glutathione S-transferase (GST), thioredoxin, staphylococcal protein A, and poly-histidine tag (Pina et al., 2021).

2.2 Approaches to optimizing post-translational modifications

Glycosylation is a key post-translational modification needed in many human therapeutic proteins. Glycosylation in plants differs from humans and possesses additional α 1,3 fucose and β 1,2 xylose modifications. This may affect the activity, stability, and immunogenic responses of the therapeutic protein (Grabowski et al., 2014). Therefore, transgenic plants and plant cell cultures were developed to remove plant-specific glycans and to introduce human glycosylation pathways to produce more complex proteins like monoclonal antibodies (Castilho and Steinkellner, 2012). For instance, antibodies (CAP256-VRC26) against human immunodeficiency virus type 1 were expressed in glycoengineered N. benthamiana. These antibodies showed equivalent neutralizing activity to mammalian-produced antibodies (Singh et al., 2020). Similarly, human-like glycosylated granulocyte colony-stimulating factor (G-CSF) was produced in N. benthamiana by co-expressing genes needed for human-specific O-glycosylated G-CSF (Ramirez-Alanis et al., 2018).

2.3 Examples of key plant-made therapeutic proteins

Many essential therapeutic proteins, vaccines, and monoclonal antibodies are produced in plant systems. A handful of these biologics are commercialized or in clinical trials (Table 1). The first plant-made drug approved for human use by U.S. Food and Drug Administration (FDA) is Elelyso (taliglucerase alfa). It was produced in genetically modified carrot cells by Protalix Biotherapeutics to treat heritable type I Gaucher’s disease (Fox, 2012). Another drug is ZMapp, a cocktail of three monoclonal antibodies produced in transgenic tobacco. Its administration completely cured Ebola infection in Rhesus macaques (Qiu et al., 2014). The other plant-made commercialized proteins include bovine trypsin (expressed in corn and marketed by Sigma Aldrich), human and animal growth factors (expressed in barley seeds and marketed by ORF Genetics), and recombinant human serum albumin (expressed in rice and marketed by Sciencell Research Laboratories). Recently, a large-scale phase 3 clinical trial of N. benthamiana produced a quadrivalent influenza vaccine that demonstrated substantial protection against influenza viruses in adults (Ward et al., 2020). These findings conclude that plant-made platforms to produce biopharmaceuticals have broad
potential but need more research and optimizations to meet market demand.

3 Heterologous expression of secondary metabolites in plants

SMs are produced from primary metabolic pathways in response to growth, development, and biotic and abiotic stresses. Several SMs have utility as therapeutics for human diseases. Many plant expression platforms like cell/suspension culture, callus culture, organ culture, hairy root culture, shoot culture, and transgenics are established for the heterologous production of SMs (Fazili et al., 2022). However, the accumulation of SMs can be enhanced further by a better understanding and optimization of metabolic pathways, the rate-limiting step(s), and genetic regulations.

3.1 Approaches to enhance the production of secondary metabolites

3.1.1 Overexpression of rate-limiting enzyme(s)

The metabolic pathways may have single or multiple rate-limiting steps, and the overexpression of crucial rate-limiting enzyme(s) may improve the production of the desired metabolite. For instance, Atropa belladonna ornithine decarboxylase (AbODC) is a rate-limiting enzyme in the biosynthesis of tropane alkaloids. Tropane alkaloids have several clinical uses such as treating Alzheimer’s disease, postoperative nausea, and motion sickness. Overexpression of AbODC significantly increased the accumulation of putrescine, N-methylputrescine, hyoscymamine, and anisodamine in A. belladonna hairy roots and transgenic plants (Zhao et al., 2020). Similarly, overexpression of hyoscyamine six hydroxylase, a key enzyme in the scopolamine biosynthetic pathway, increased the production of scopolamine alkaloid in the hairy roots of Datura innoxia (Li et al., 2020). Camptothecin is an FDA-approved pharmaceutically important monoterpenoid indole alkaloid having potent anticancer properties. The expression of two key camptothecin biosynthetic genes, OpG10H and OpSLS, greatly enhanced its production (up to 3.5 mg/g) in transgenic Ophiorrhiza pumila hairy roots (Shi et al., 2020).

3.1.2 Overexpression of transcription factors

Transcription factors are critical regulators of many metabolic pathways, and their expression can enhance SMs production. The overexpression of OpWRKY2 activated a camptothecin pathway gene, OpTDC. It resulted in a three-fold increase in camptothecin accumulation in Ophiorrhiza pumila hairy roots (Li et al., 2021). In another study, astragalosides production was increased in Astragalus membranaceus hairy roots by overexpressing Arabidopsis transcription factor MYB12, Production of anthocyanin pigment 1 (PAP1), and maize leaf color (Lc) transcription factors (Li et al., 2022).

3.1.3 Overexpression of MicroRNAs

MicroRNAs (miRNAs) are small noncoding RNAs important for gene regulation. They play crucial roles in growth, development, and stress responses, as well as the regulation of secondary metabolite pathways (Hossain et al., 2022). Small RNA sequencing of three grape varieties with different anthocyanin and flavonoid content identified that the grape lines with high anthocyanin content abundantly express

---

**TABLE 1 Examples of plant-made vaccines, antibodies, and enzymes at various human clinical stages.**

| Product                        | Plant              | Development stage | Purpose                                                                 | References                  |
|-------------------------------|--------------------|-------------------|------------------------------------------------------------------------|-----------------------------|
| Bacillus anthracis vaccine    | N. benthamiana     | Phase 1           | Protection from anthrax                                                 | Paolino et al., 2022        |
| Vibrio cholerae vaccine       | Rice               | Phase 1           | Protection from cholera                                                 | Yuki et al., 2022           |
| COVID 19 vaccine              | N. benthamiana     | Phase 3           | Protection from COVID19                                                 | Hager et al., 2022          |
| TNF fusion protein (OPRX-106) | Tobacco BY2 cells  | Phase 2a          | Treatment of ulcerative colitis                                         | Almoon et al., 2021         |
| Monoclonal antibodies against HIV and HSV | N. benthamiana | Phase 1           | Protection from HIV-1, HSV-1, and HSV-2                                 | Polach et al., 2021         |
| Pegunigalsidase alfa (PEGylated, α-galactosidase A) | ProCellEx system | Phase 1/2         | Treatment of Fabry disease                                              | Schillmann et al., 2019     |
| ZMapp (a triple monoclonal antibody) | N. benthamiana | Phase 1           | Treatment of Ebola virus disease                                        | Molangu et al., 2019        |
| Plasmidium falciparum vaccine | N. benthamiana     | Phase 1           | Protection from malaria                                                 | Chichester et al., 2018     |
| Taliglucerase alfa            | Carrot cells       | Phase 3           | Treatment of Gaucher disease                                            | Zimean et al., 2018         |
| HIV-neutralizing antibody     | N. tabacum         | Phase 1           | Protection from HIV                                                     | Ma et al., 2015             |
| B-cell follicular lymphoma     | N. benthamiana     | Phase 1           | Treatment of Non-Hodgkin’s lymphoma                                     | Tsue et al., 2015           |
| human acetylcholinesterase-R (PRX-105) | N. tabacum cell line | Phase 1           | Treatment against Organophosphorous (OP) poisoning                      | Atsmon et al., 2015         |

---

Frontiers in Plant Science
two miRNAs, miR828 and miR858. These miRNAs target the MYB114 transcription factor, which is a negative regulator of anthocyanin biosynthesis. Hence, overexpression of these miRNAs increased anthocyanin accumulation (Tirumalai et al., 2019). In another study, overexpression of miR156 isolated from Medicago truncatula increased 8.3 folds in total anthocyanins production in transgenic poplar plants compared to wild-type plants (Wang et al., 2020).

### 3.1.4 Gene editing

CRISPR/Cas9 mediated targeted mutagenesis has been developed to enhance the production of valuable metabolites in several plant species. *Atropa belladonna* produces a small amount of hyoscyamine and its structural analogs, anisodamine, and scopolamine. Zeng et al. (2021) used CRISPR/Cas9 to disrupt hyoscyamine 6β-hydroxylase (AbH6H). The transgenic plants produced a significantly higher hyoscyamine content but without anisodamine and scopolamine alkaloids (Zeng et al., 2021). In another study, Karlson et al. (2022) used CRISPR/Cas9 to silence cinnamate-4-hydroxylase (C4H) for enhanced flavonoid production into *N. tubacum* cell suspension. C4H silenced cells produced a significantly higher concentration of cinnamic acid, chlorogenic acid, pinostrobin, and naringenin than wild-type cells (Karlson et al., 2022).

### TABLE 2 Enhancement of secondary metabolites by various molecular approaches.

| Molecular Approach | Gene/Transcription factor/miRNA | PlantCulture type | Secondary metabolite | Fold increase | Reference |
|---------------------|---------------------------------|-------------------|----------------------|---------------|-----------|
| Overexpression of key enzyme(s) | Δ^{14}-reductase | Fenugreek Hairy roots | Diosgenin | 3 | Nasiri et al., 2022 |
| | Columbamine O-methyltransferase | N. tabacum Transgenic plant | Total alkaloids | 1.09- 1.83 | Tu TQ et al., 2022 |
| | 12-Oxophytodienoate reductase | Echium plantagineum Hairy roots | Acetylshekolin | 2 | Fu et al., 2022 |
| | Geranylgeranyl diphosphate synthase (CrGGPPS2) | Catharanthus roseus Transgenic plant | Vindoline Catharanthine Vinblastine | 1.2- 2.5 1.3- 3.5 1.25-1.5 | Kumar et al., 2020 |
| | Tobacco lipid transfer protein (NtLTP1) | Orange mint Transgenic plant | Monoterpenes | ——— | Hwang et al., 2020 |
| | AtDXS, AtHDR, AtGGPS, JcCAS | N. benthamiana Transgenic plant | Squalene and botryococcene | 2 | Kempinski and Chappell, 2019 |
| | Triterpene synthase, farnesyl diphosphate synthase, 1-deoxyxylulose 5-phosphate synthase | Arabidopsis thaliana Transgenic plant | Shikimic acid | 4.8 | Dhakarey et al., 2022 |
| | PgMyb308 | Punica granatum Hairy roots | Anthocyanin and flavonoids | 2.5 | Badim et al., 2022 |
| | VviNAC17 | Grape berry Cell suspension culture | Stilbenes | 3.4-4 5.9-13.9 | Ananev et al., 2022 |
| | VaMyb40, VaMyb60 | Vitis amurensis Callus culture | Baicalin | 3.24 3.42 3.46 | Park et al., 2021 |
| | BcERF3 | Bupleurum chinense Hairy roots | Baicalin Baicalin | 5.53 5.80 | Zhou et al., 2021 |
| | SmMYB1 | Salvia miltiorrhiza Hairy roots | Total phenolic content | ——— | Han et al., 2022 |
| | ZmLe | Scutellaria baicalensis Hairy roots | Baicalin Baicalin Wogonin | 3.24 3.42 3.46 | Park et al., 2021 |
| | AtPAP1 | Baicalin | 5.53 5.80 2.29 | | |
| Overexpression of transcription factors | | | | | |
| | VvbZIP36 | Vitis vinifera Transgenic plant | Anthocyanins | ——— | Tu M et al., 2022 |
| | GmF3H1, GmF3H2 and GmFNSII-1 | Soybean Transgenic plant | Isoflavone | ——— | Zhang et al., 2020 |
3.1.5 Expression in genetically engineered microalgae

Although not plants, microalgae which are also photosynthetic organisms can be leveraged to produce a broad range of secondary metabolites of pharmaceutical importance (Sreenikethanam et al., 2022). The Cannabis sativa plant naturally produces cannabinoids that treat nausea and vomiting caused by cancer chemotherapy, neuropathic pain, and spasticity. Furthermore, cannabinoids also possess anticancer properties (Mangal et al., 2021). Genetically engineered Microalgae were recently used for the heterologous production of cannabinoids (Bolaños-Martínez et al., 2022). Microalgae system is advantageous as they have limited growth needs such as CO2 and few organic compounds.

3.2 Examples of key plant-derived secondary metabolites

Plant SMs are useful as treatments for several diseases, including cancer, diabetes, COVID-19, arthritis, and neurological and cardiovascular disorders (De Filippis, 2016). To date, only paclitaxel has been produced on a commercial scale. It is included in the WHO list of essential medicines and is used to treat different cancers. Phyton Biotech is commercially producing paclitaxel (trade name Taxol® by Bristol-Myers Squibb) using plant cell fermentation technology based on cell lines of Taxus chinensis v. marei (https://phytonbiotech.com/). The other SMs produced in different expression systems showed higher expression than native plants (Table 2), but more efforts are still needed to produce SMs at an industrial scale.

4 Conclusion

Despite the advantages of plant-based expression platforms, only a few commercial products passed the regulatory approvals and reached the market (Schillberg et al., 2019). In our perspective, a critical barrier to commercialization using plant-based expression platforms comes down to investment returns. Any profitable company wants products of high quality, reliability, and quantity at a low cost. Currently, the market favors mammalian and bacterial platforms as they have a long and successful history of making pharmaceuticals. Furthermore, these platforms have demonstrated batch-to-batch consistency and safety, which is especially important for drug formulations for human use. Plant-based expression platforms face higher capital costs for raw materials and infrastructure, downstream process optimization costs, lower market demand, public acceptance, more biosafety needs, and regulatory approvals. Industries often are wary of switching from well-established platforms to plant-based platforms. Plant-based expression platforms need to demonstrate greater net economic return compared to prokaryotic and mammalian systems to be competitive. With recent advancements in genetic and genomic tools, the heterologous production of high-value proteins and metabolites in plant expression systems has gained traction. The platforms can be deployed to mass-produce (scalable) biopharmaceuticals in a shorter timeframe and can be relatively cost-effective compared to other conventional cell culture-based systems. This is particularly helpful during rapid response situations such as during pandemics. New approaches have also allowed for improvements in target protein stability and accumulation, post-translational modifications, and downstream recovery/purification of the proteins. We anticipate increasing market demand for high-value therapeutics and bioproducts that can boost commercial interest in plant-based expression platforms.

Author contributions

KM conceptualized and supervised the study. AK, SS, and CP conducted the study and prepared the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This study was supported in part by funds from USDA NIFA (HATCH 1023984), Texas A&M AgriLife Research Insect-vectored Disease Seed Grants (114185-96210), and the Texas A&M AgriLife Institute for Advancing Health Through Agriculture to KM.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Buranapraditkun, S., Boonkrai, C., et al. (2021). Functional characterization of downstream processing tags in protein purification. Metab. Eng., 143, 2507–2534. doi:10.1016/j.mib.2021.03-0710-7

Mardonova, E. S., Blokhina, E. A., Tsybalova, I. M., Perret, H., Lomonossoff, G. P., and Ravin, N. V. (2017). Efficient transient expression of recombinant proteins in plants by the novel pELL vector based on the genome of potato virus X. Front. Plant Sci. 8. doi:10.3389/fpls.2017.00247

Matsou, K. (2022). CRISPR/Cas9-mediated knockout of the DCL2 and DCL4 genes in nicotiana benthamiana and its productivity of recombinant proteins. Plant Cell Rep. 40, 307–317. doi:10.1007/s00299-021-02819-y

Mirzaei, M., Osmani, Z., Freibortova, I., and Freibort, I. (2022). Recent advances in molecular farming using monocot plants. Biotechnol. Adv. 58, 107913. doi:10.1016/j.biotechadv.2022.107913

Mulang, S., Dodd, L. E., Davey, R. T. J., Tshiani Mbaya, O., Proschlan, M., Mukadi, D., et al. (2019). A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293–2303. doi:10.1056/NEJMoa190993

Nasiri, Z., Dorani Ularai, E., Ofoghi, H., and Davarpanah, S. J. (2020). Expression of novel Illh yeast fusion protein using plant viral vector and study of its anticancer effect. Plant Tiss. Cult. Organ Cult. 143, 97–108. doi:10.1007/s11114-020-01900-8

Nasiri, A., Rashidi-Monfared, S., Ebrahimi, A., Charkhabi, N. F., and Moieni, A. (2022). Metabolic engineering of the diosgenin biosynthesis pathway in trigonella foenum-graceum hairy root cultures. Plant Sci. 323, 111410. doi:10.1016/j.plantsci.2022.111410

Padilla, C. S., Damsai, M. B., Yang, Z. N., Molina, J., Berquist, B. R., White, E. L., et al. (2020). High-level production of recombinant snordiop lectin in sugarcane and energy cane. Front. Bioeng. Biotechnol. 8. doi:10.3389/fbioe.2020.00977

Paulino, K. M., Regules, J. A., Moon, J. E., Ruck, R. C., Bennett, J. W., Remich, S. A., et al. (2022). Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against bacillus anthracis: a phase I dose-escalation study in healthy adults. Vaccine 40, 1866–1871. doi:10.1016/j.vaccine.2022.01.047

Park, C. H., Xu, H., Yeo, H. J., Park, Y. E., Hwang, G. S., Park, N. I., et al. (2021). Enhancement of the flavone contents of scotsllaria baikalensis hairy root via metabolic engineering using maize le and arabidopsis PAP1 transcription factors. Metab. Eng. 64, 64–73. doi:10.1016/j.mib.2021.01.003

Phakhum, T., Bulaon, C. J. I., Chororattanakulchai, N., Shannmugaraj, B., Buranapraditkun, S., Boonkrai, C., et al. (2021). Functional characterization of pembroliuzumab produced in nicotiana benthamiana using a rapid transient expression system. Front. Plant Sci. 12, 736299. doi:10.3389/fpls.2021.736299

Pina, A. S., Batalla, I. L., Dias, A. M. G. C., and Roque, A. C. A. (2021). “Affinity tags in protein purification and peptide enrichment: An overview,” in Protein downstream processing, vol. 2178. Ed. N. E. Labrou (New York, NY: Humana).

Polich, J. A., Cu-Uvin, S., Moench, T. R., Tashima, K. T., Marathe, J. G., Guthrie, K. M., et al. (2021). Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention microbicide film (MB66): a phase 1 randomized trial. PLoS Med. 18, e1003495. doi:10.1371/journal.pmed.1003495

Qu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J. B., et al. (2014). Long-term safety and efficacy of a monoclonal antibody-based vaginal multipurpose prevention conjugate vaccines for follicular lymphoma. Biomed. Res. Int. 2015, 648143. doi:10.1056/NEJMoa1503414

Wang, X., Karki, U., Abegunrarine, H., Unold,CoFcre, I., and Xu, J. (2021). Plant cell-secreted stem cell factor stimulates expansion and differentiation of hematopoietic stem cells. Process Biochem. 100, 39–48. doi:10.1016/j.procbio.2020.09.029

Wang, Y., Liu, W., Yang, X., Wang, R., Wu, Z., Wang, H., et al. (2020). MiR156 regulates anthocyanin biosynthesis through SPL targets and other miRNAs in poplar. Hortic. Res. 7, 118. doi:10.1038/s41438-020-00341-w

Ward, B. J., Makarkov, A., Séguin, A., Pillet, S., Trépanier, S., Dhalliwal, J., et al. (2020). Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥ 65 years). Two multicentre, randomised phase 3 trials. Lancet 396, 1491–1503. doi:10.1016/S0140-6736(20)30214-6

Webster, G. R., Teh, A. Y. H., and Ma, J. K. C. (2017). Synthetic gene design—the rationale for codon optimization and implications for molecular pharming in plants. Biotechnol. Bioeng. 114, 492–502. doi:10.1002/bit.26183

Xu, J., Towler, M., and Weathers, P. J. (2018). “Platforms for plant-based protein production,” in Bioprocessing of plants in vitro systems (Cham: Springer), 509–548. doi:10.1007/978-3-319-4600-1_14

Yuki, Y., Nojima, M., Kashima, K., Sugisata, K., Maruyama, S., Kurokawa, S., et al. (2022). Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults. Vaccine 40, 3372–3379. doi:10.1016/j.vaccine.2022.04.051

Zahmanov, G., Mazalovska, M., Takova, K., Toneva, V., Minkov, I., Perret, H., et al. (2022). Efficient production of chimeric hepatitis B virus-like particles bearing an epitope of hepatitis e virus capsid by transient expression in nicotiana benthamiana. Life 11, 64. doi:10.3390/life110100064

Zeng, L., Zhang, Q., Jiang, C., Zheng, Y., Zuo, Y., Qin, J., et al. (2021). Development of atropa belladonna l. plants with high-yield hyoscyamine and without its derivatives using the CRISPR/Cas9 system. Int. J. Mol. Sci. 22, 1731. doi:10.3390/ijms22041731

Zhang, P., Du, H., Wang, J., Pu, Y., Yang, C., Yan, R., et al. (2020). Multiplex CRISPR/Cas9-mediated metabolic engineering increases soybean isoflavone content and resists soybean mosaic virus. Plant Biotechnol. J. 18, 1384–1395. doi:10.1111/pbi.13102

Zhao, T., Li, S., Wang, J., Zhou, Q., Yang, C., Bai, F., et al. (2020). Engineering tropane alkaloid production based on metabolic characterization of ornithine decarboxylase in atropa belladonna. ACS Synth. Biol. 9, 437–448. doi:10.1021/acsbio.9b00461

Zhoub, W., Shi, M., Deng, C., Lu, S., Huang, F., Wang, Y., et al. (2021). The methyl jasmonate-responsive transcription factor SmMYB11 promotes phloem cell biosynthesis in salvia miltiorrhiza. Biotechnol. J. 18, 1384–1395. doi:10.1002/biot.202000345

Zirman, A., Gonzalez-Rodriguez, D. E., Abrahom, A., Cooper, P. A., Varughese, S., Giraldo, P., et al. (2018). Long-term safety and efficacy of talcufficient ala in pediatric gauhcer disease patients who were treatment-naive or previously treated with imiglucerase. Blood Cells Mol. Dis. 68, 163–172. doi:10.1016/j.bcmd.2016.10.005